FKBP15 Antibody / FKBP133

Overview

FKBP15, also known as FKBP133, is a member of the FK506-binding protein family, a group of proteins initially identified as immunophilins, targets for the immunosupressant drugs FK506 and Rapamycin. FKBP15 is expressed in the developing nervous system and contains a domain similar to Wiskott-Aldrich syndrome protein homology region 1 (WH1) in addition to the FK506-binding protein motif. FKBP15 is distributed along the axonal shafts and partially co-localizes with F-actin in the growth cones of dorsal root ganglion neurons; overexpression of FKBP15 resulted in the number of filopodia in transfected neurons, suggesting that FKBP15 modulates growth cone behavior. FKBP15 has also been shown to associate with both microtubules and the actin filament systems and disruption of its expression by RNAi resulted in delayed transport of early endosomes in HeLa cells indicating that FKBP15 is also involved in the transport of early endosomes. At least three isoforms of FKBP15 are known to exist.

This anti-FKBP133 antibody is supplied as Antigen affinity purified (Rabbit, Polyclonal (rabbit origin), Rabbit IgG, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.

Key elements and design rationale

• Target: FKBP133
• Format: Antigen affinity purified
• Localization: Cytoplasmic
• Species reactivity: Human, Mouse, Rat
• Applications (listed): WB, IHC-P, IF, FACS, Direct ELISA
• Conjugate: Unconjugated
• Clone and antibody class: Polyclonal (rabbit origin), Rabbit IgG

Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.

Biological background

FKBP133 is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.

Research relevance and current trends

• Profiling FKBP133 expression across model systems, perturbations, and time points to support mechanistic hypotheses.
• Combining antibody-based detection with multi-omics or imaging readouts to link FKBP133 signal with phenotype.
• Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.

Common research applications

• WB
• IHC-P
• IF
• FACS
• Direct ELISA

Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.

Notes for experimental interpretation

• Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
• Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
• Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.